Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2023 | Demyelinating disorders: Impact of a novel biomarker on clinical practice

Anne-Katrin Pröbstel, MD, University Hospital of Basel, University of Basel, Basel, Switzerland, discusses the impact of myelin oligodendrocyte glycoprotein (MOG) IgA on clinical practice in demyelinating disease. MOG-IgA is found in patients with a clinically distinct syndrome, which suggests that it could be a novel biomarker for patients with double seronegative central nervous system demyelination. These patients often have overlapping features with neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disorders (MOGAD)patients, so MOG-IgA could potentially be used to differentiate between these disease subtypes. This interview took place at the American Academy of Neurology Annual Meeting 2023 in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.